RxDoctor Payments DataLook up a doctor →

Bryan Hoelzer, MD

Interventional Pain Medicine · Vineyard, UTNPI 1770558090

Payments from drug & device makers

$717,549in general payments, 2019–2025

Across 987 payments — averaging $727.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$492K
  • Nevro Corp.$205K
  • Medtronic$10K
  • Painteq LLC$8K
  • Relievant Medsystems, Inc.$1K
  • Abbott$309
  • plus $790 from 10 others

What the payments were for

  • Consulting fees$116,23416%
  • Speaking & faculty fees$506,01971%
  • Travel & lodging$72,35610%
  • Food & beverage$17,4192%
  • Education$5,5071%
  • Entertainment$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$717,549 in reported general payments places this provider in the 95th percentile of 26 interventional pain medicine providers in Utah.

See all interventional pain medicine providers in Utah

Medicare billing

Part B allowed, 2024
$213,696
Medicare patients
381
Services billed
2,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl12$9,182
Buprenorphine31$9,135
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen60$3,825
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen89$2,311
Diclofenac Sodium117$1,787
Pregabalin81$1,455
Gabapentin65$1,213
Tizanidine Hcl102$1,115
Oxycodone Hcl43$841
Tramadol Hcl84$819
Methocarbamol41$549
Buprenorphine Hcl16$501
Celecoxib19$422
Meloxicam19$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$22$9,18212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 26 interventional pain medicine providers in Utah.

Other interventional pain medicine in Vineyard

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →